(Bloomberg) -- Pfizer Inc. failed to convince advisers to the US Food and Drug Administration to support a dramatic expansion in the use of its prostate cancer drug, a setback that could scuttle ...

An eight-member panel voted unanimously against wider use of Pfizer’s Talzenna in advanced prostate cancer. Elsewhere, U.K.

After an apparent accidental early release, Pfizer has revealed phase 1 data showing its investigational candidate, alongside Xtandi, reduced prostate cancer progression by 49%. The data ...

Astellas Pharma (ALPMY) and Pfizer (PFE) announced longer-term follow-up results from an open-label extension of the Phase 3 ...

In its latest setback, Merck has announced ... in combination with Astellas/Pfizer’s Xtandi (enzalutamide) in metastatic castration-resistant prostate cancer (mCRPC) – its last remaining ...

A U.S. FDA panel of independent experts beat back an effort by Pfizer (NYSE:PFE) to expand the patient population for its prostate cancer treatment Talzenna (talazoparib). Members of the Oncologic ...

Pfizer also has experienced multiple setbacks in its attempts to develop ... Nurtec ODT for migraine and Xtandi for prostate cancer. Adjusted earnings for 2024 will be $2.75 to $2.95 a share ...

is the first and only androgen receptor inhibitor to demonstrate an overall survival benefit at five years in men with metastatic hormone-sensitive prostate cancer Data continue to show wide ...

On the regulatory front this year, a Pfizer spokesperson said the company anticipates three regulatory decisions in prostate cancer, colorectal cancer and non-Hodgkin lymphoma, as well as seven Phase ...

cervical and prostate cancers. “At Pfizer, we partner across the oncology community to meet the needs of people with cancer and help everyone have access to quality cancer care,” said Jeffrey ...